D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia
ConditionAML, Adult
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorAssiut University
About this trial
1. The effect of D-index on the onset and severity of FN in AML patients. 2. Relationship between the c-D-index and duration of FN in AML patients. 3. Correlation between D-index and MDR. 4. Correlation between D-index and invasive fungal infection. 5. Comparison of FN in different treatment protocols for AML using D-index. 6. Prediction of pulmonary, fungal or blood stream infection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult Patients (≥18 years) newly diagnosed as acute myeloid leukemia according to WHO 2016 diagnostic criteria.
Hematologic diagnosis of de novo AML.
Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
Standard induction chemotherapy (7+3 regimen) or consolidation regimens (HiDAC).
Disqualifiers
None
Trial population
All patients meeting the inclusion criteria will be recruited in the study. The period of data collection will be continued for 12 months.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
The effect of D-index on the onset and severity of FN in AML patients.
Determine if the D-index can predict the onset, severity, duration and complications of febrile neutropenia
Time frame
during the period of chemotherapy completion, an average of 1 yearLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: